• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman

    3/16/23 5:00:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials
    Get the next $TMO alert in real time by email

    FORT LAUDERDALE, Fla. and Sacramento, Calif., March 16, 2023 /PRNewswire/ -- Gemini BioProducts Holding, Inc. ("GeminiBio" or the "Company"), a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Florida-based healthcare private equity firm, announced the appointment of Cory Stevenson as Executive Chairman of the Board of Directors.

    (PRNewsfoto/BelHealth Investment Partners)

    GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman

    Mr. Stevenson joined the Board of GeminiBio in 2022 and has been working closely with the GeminiBio management team as they prepare to complete a three-phase buildout that addresses the long-term capacity needs in the biopharma and cell/gene therapy marketplace. Previously, Mr. Stevenson served as President of the BioProduction Division of Thermo Fisher Scientific (NYSE:TMO), a world leader in serving the biopharma sector, with annual revenue of more than $40 billion. During Cory's tenure, the BioProduction business grew from $200 million in revenues to over $2.5 billion annually.

    Harold S. Blue, Managing Partner of BelHealth Investment Partners said, "We are fortunate to have Cory expand his role and guide our strategy at GeminiBio. Cory has been very helpful during the last year as a board member and I am excited that he will be taking a more active role. Also, given that Cory worked directly with GeminiBio's CEO, Brian Parker, while at Thermo Fisher, this was a natural fit."

    Cory Stevenson, Executive Chairman of GeminiBio added, "I am delighted to expand my role at GeminiBio after working closely with Brian and the rest of the team since I joined the Board. With the completion of its 57,000-square-foot manufacturing facilities, GeminiBio is positioning itself as a vendor delivering much-needed critical solutions to the global biopharma industry. I am looking forward to this exciting next phase at GeminiBio."

    About BelHealth Investment Partners

    BelHealth Investment Partners, based in Fort Lauderdale, Florida, is a healthcare private equity firm focused on lower middle market companies. BelHealth has a unique combination of investing, executive management, and entrepreneurial experience. BelHealth acquires majority positions in entrepreneur-owned companies that it believes will benefit from its extensive operating and private equity investment expertise. For more information, visit www.belhealth.com.

    About GeminiBio

    Founded in 1985, GeminiBio serves the global biotechnology industry, from basic research to commercial production, with a focus on helping our customers accelerate the development of life enhancing biotherapeutics by streamlining and improving their cell culture and process liquid manufacturing workflows. The company's products are organized into two core verticals – Cell Culture Solutions and Process Liquid Solutions. Located in West Sacramento, California, GeminiBio has 57,000 square feet of cGMP manufacturing space that is segregated between animal origin free and animal component manufacturing. GeminiBio is an ISO 13485 certified, FDA registered Class 1 Medical Device Manufacturer, aligned with 21 CFR Part 820. For more information, visit www.geminibio.com.

    Contact:

    BelHealth: Inder Tallur, [email protected]

    GeminiBio: [email protected]

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/geminibio-appoints-industry-veteran-cory-stevenson-as-executive-chairman-301774586.html

    SOURCE BelHealth Investment Partners

    Get the next $TMO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TMO

    DatePrice TargetRatingAnalyst
    7/24/2025$510.00Buy → Hold
    HSBC Securities
    7/11/2025$590.00Sector Perform → Sector Outperform
    Scotiabank
    7/9/2025$460.00Buy → Neutral
    UBS
    1/10/2025$630.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/14/2024Buy
    Redburn Atlantic
    10/1/2024$680.00Overweight
    Stephens
    8/28/2024$670.00Overweight
    Wells Fargo
    More analyst ratings

    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Weisler Dion J

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      7/1/25 4:23:49 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Sperling Scott M

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      7/1/25 4:21:18 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 4 filed by Director Keith R. Alexandra

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      7/1/25 4:18:48 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

      Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

      7/23/25 9:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Reports Second Quarter 2025 Results

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025. Second Quarter Highlights Second quarter revenue grew 3% to $10.85 billion. Second quarter GAAP diluted earnings per share (EPS) grew 6% to $4.28. Second quarter adjusted EPS was $5.36. Delivered excellent operational performance in the quarter, reflecting active management of our company in the macroenvironment demonstrating the strength of our proven growth strategy and the power of the PPI Business System. Advanced our proven growth strategy, launching a range of high-impact innovation, strengthening our industr

      7/23/25 6:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing

      Thermo Fisher to Acquire Sanofi's Steriles Manufacturing Site in Ridgefield, New Jersey to Produce Critical Medicines for Sanofi Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additional U.S. drug product manufacturing. The terms of the deal were not disclosed. Under the agreement, Thermo Fisher will acquire Sanofi's steriles manufacturing site in Ridgefield, New Jersey and will continue to manufacture a portfolio of therapies for Sanofi. In addition, Thermo Fisher will ex

      7/16/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      2/21/25 4:19:32 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Boxer Michael A bought $2,105 worth of shares (4 units at $526.15), increasing direct ownership by 0.03% to 13,101 units (SEC Form 4)

      4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

      10/6/23 4:23:51 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $TMO
    SEC Filings

    See more
    • Thermo Fisher downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Thermo Fisher from Buy to Hold and set a new price target of $510.00

      7/24/25 9:29:26 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher upgraded by Scotiabank with a new price target

      Scotiabank upgraded Thermo Fisher from Sector Perform to Sector Outperform and set a new price target of $590.00

      7/11/25 7:57:15 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher downgraded by UBS with a new price target

      UBS downgraded Thermo Fisher from Buy to Neutral and set a new price target of $460.00

      7/9/25 8:19:41 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Inc filed SEC Form 8-K: Leadership Update

      8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      7/23/25 4:16:06 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      7/23/25 6:03:44 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form 11-K filed by Thermo Fisher Scientific Inc

      11-K - THERMO FISHER SCIENTIFIC INC. (0000097745) (Filer)

      6/17/25 2:30:55 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Leadership Updates

    Live Leadership Updates

    See more
    • Thermo Fisher Scientific's Chief Financial Officer, Stephen Williamson, to Retire in Early 2026

      Jim Meyer to Become Chief Financial Officer, Effective March 1, 2026 Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that Stephen Williamson, senior vice president and chief financial officer (CFO), has decided to retire from the company, effective March 31, 2026. The company's board of directors has approved the appointment of Jim Meyer, currently vice president of financial operations, to succeed Williamson as CFO, effective March 1, 2026. Williamson, age 58, has led Thermo Fisher's global finance organization as CFO since 2015. He joined the company in 2001 as Vice President, European Financial Operations. To ensure a seamless transition

      7/23/25 9:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • 908 Devices Appoints Christopher D. Brown to its Board of Directors

      908 Devices Inc. (NASDAQ:MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces that it has appointed Christopher D. Brown, PhD, Vice President, Analytics R&D at Repligen Corporation (NASDAQ:RGEN), and a 908 Devices Co-founder, to serve on its Board of Directors, effective immediately. Dr. Brown co-founded 908 Devices and served as the company's Chief Technology Officer & Vice President of Research & Development from February 2012 to March 2023, and as its Chief Product Officer from March 2023 until March 2025 when Repligen purchased the company's bioprocessing portfolio. Prior to 908 Devices, Dr. Brown was a platform architect at Apple Inc. (NASDAQ:AAPL) lead

      6/16/25 8:00:00 AM ET
      $AAPL
      $MASS
      $RGEN
      $TMO
      Computer Manufacturing
      Technology
      Industrial Machinery/Components
      Industrials
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components

    $TMO
    Financials

    Live finance-specific insights

    See more
    • Thermo Fisher Scientific Reports Second Quarter 2025 Results

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025. Second Quarter Highlights Second quarter revenue grew 3% to $10.85 billion. Second quarter GAAP diluted earnings per share (EPS) grew 6% to $4.28. Second quarter adjusted EPS was $5.36. Delivered excellent operational performance in the quarter, reflecting active management of our company in the macroenvironment demonstrating the strength of our proven growth strategy and the power of the PPI Business System. Advanced our proven growth strategy, launching a range of high-impact innovation, strengthening our industr

      7/23/25 6:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific Declares Quarterly Dividend

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on October 15, 2025, to shareholders of record as of September 15, 2025. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the

      7/10/25 4:15:00 PM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 23, 2025

      Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the second quarter 2025 before the market opens on Wednesday, July 23, 2025, and will hold a conference call on the same day at 8:30 a.m. ET. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 523661. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of our website under t

      7/1/25 8:00:00 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials

    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

      SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

      2/9/23 11:35:13 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials
    • SEC Form SC 13G/A filed

      SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

      2/10/21 11:57:23 AM ET
      $TMO
      Industrial Machinery/Components
      Industrials